Vascular Unit, Division of Surgery and Interventional Science, Royal Free Hospital, University College London (Royal Free Campus), Pond Street, London NW3 2QG, UK.
Cardiol Res Pract. 2012;2012:213785. doi: 10.1155/2012/213785. Epub 2012 Feb 22.
Erythropoietin (EPO) has tissue-protective properties, but it increases the risk of thromboembolism by raising the haemoglobin concentration. New generation of EPO derivatives is tissue protective without the haematopoietic side effects. Preclinical studies have demonstrated their effectiveness and safety. This paper summarizes the development in EPO derivatives with emphasis on their potential use in critical limb ischaemia.
促红细胞生成素（EPO）具有组织保护特性，但它通过提高血红蛋白浓度增加血栓栓塞的风险。新一代的 EPO 衍生物具有组织保护作用，而没有血液学副作用。临床前研究已经证明了它们的有效性和安全性。本文总结了 EPO 衍生物的发展，重点介绍了它们在严重肢体缺血中的潜在用途。
